No Chinese Herbs or Other Herbal Agents Are Recommended for Suppressing or Reversing Metastatic Cancer
Current clinical practice guidelines for metastatic cancer management do not include any Chinese herbs or herbal medicines as standard treatment options, and no herbal agent has demonstrated sufficient clinical evidence to reverse or suppress metastatic disease in humans. The established guidelines for metastatic colorectal cancer 1 and hepatocellular carcinoma 2 exclusively recommend evidence-based interventions including surgery, systemic chemotherapy, targeted therapies (lenvatinib, sorafenib, regorafenib), immunotherapy combinations (atezolizumab plus bevacizumab), and local ablative techniques—with no mention of herbal therapies.
Why Guidelines Exclude Herbal Medicine
The absence of herbal recommendations in authoritative guidelines reflects a critical evidence gap:
- No high-quality randomized controlled trials have demonstrated that any herbal agent can suppress or reverse established metastatic cancer in humans
- The one clinical study examining Chinese herbs in metastatic colorectal cancer 3 showed correlation with survival but was retrospective and observational—insufficient to establish causation or clinical efficacy
- All other supporting evidence comes from preclinical laboratory and animal studies 4, 5, 6, 7, 8, which frequently fail to translate to human benefit
What the Research Actually Shows
While laboratory studies suggest certain mechanisms, these findings remain unvalidated clinically:
- Mechanistic studies only: Research indicates Chinese herbs may theoretically modulate epithelial-mesenchymal transition, tumor-associated macrophages, and signaling pathways (PI3K/AKT, Wnt/β-catenin, TGF-β) 4, 5, 6
- No reversal demonstrated: Even in preclinical models, herbs showed growth suppression or slowed progression—not reversal of established metastases 7, 8
- Standardization problems: TCM formulations lack consistent composition, dosing, and quality control, making clinical application impossible 8
Critical Clinical Pitfalls
Do not delay or substitute proven therapies with herbal treatments. Patients with metastatic cancer require immediate evidence-based intervention:
- For metastatic colorectal cancer: systemic chemotherapy (FOLFOX/FOLFIRI), targeted agents, or immunotherapy combinations 1
- For advanced hepatocellular carcinoma: atezolizumab-bevacizumab, lenvatinib, or sorafenib as first-line treatment 2
- Surgical resection or ablation when technically feasible 1, 2
The retrospective study showing improved survival with Chinese herbs 3 cannot establish whether herbs provided benefit or whether patients receiving herbs simply had better baseline prognosis, access to care, or concurrent standard treatments.
The Bottom Line for Clinical Practice
No herbal medicine—Chinese or otherwise—has sufficient evidence to recommend for treating metastatic cancer. The most recent guidelines 1, 2 and the current evidence base support only conventional oncologic therapies. While future research may identify active compounds from traditional medicines, current patients require proven treatments that demonstrably improve survival and quality of life.
If patients inquire about herbal supplements, counsel them that these remain investigational, lack clinical validation, may interact with chemotherapy, and should never replace standard cancer treatment.